Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density

NCT00043186 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

412

Enrollment

INDUSTRY

Sponsor class

Conditions

Low Bone Mineral Density

Interventions

DRUG: Placebo
DRUG: Denosumab
DRUG: Alendronate

Sponsor

Amgen